Although between-patient heterogeneity is common in clinical trials, most phase II designs assume patients are homogeneous [1] [2] [3] [4] [5] [6] . This may lead to severe errors when evaluating an experimental treatment, E. A design that ignores known differences between prognostic subgroups runs substantial risks of reaching erroneous conclusions about the effects of E within subgroups. Alternatively if, a priori, there is no known difference between subgroups, assuming one overall response rate does not accommodate the possibility that the effectiveness of E may differ between subgroups. We will describe two Bayesian designs [7 ,8] that address these settings by accounting for patient heterogeneity.
have the same mean, 0.25, but the beta(0.25, 0.75) has an effective sample size equal to one patient, whereas the beta (20, 60) has an effective sample size of 80 patients, reflecting almost no knowledge about u E and substantial knowledge about u S .
Once data have been observed, Bayes' Law is applied to compute a new probability distribution, posterior(u j data), that quantifies what has been learned about u from the data. The vertical bar can be read to mean 'given that one knows' or 'given that one has observed.' The posterior is used to make statistical inferences about u. In contrast, classical 'frequentist' statistics considers u to be fixed but unknown. Advances in computational methods have greatly accelerated practical application of Bayesian methods in recent years, especially in biostatistics [12] and clinical trials [13] [14] [15] [16] . The Bayesian paradigm provides a natural framework for making decisions sequentially based on accumulating data during a clinical trial, as is done in a phase II trial with interim monitoring rules, as Bayes' Law may be applied repeatedly by using the posterior obtained after each stage as the prior for the next stage. In the above example, a Bayesian rule to stop the trial of E due to futility might take the form Pr(u S þ 0.15 < u E j data) < 0.05, which says to stop accrual if a 0.15 improvement of E over S in response probability is unlikely, given the observed data. Figure 1b gives the posteriors of u E that would result if 3 out of 10 (30%), 8 out of 20 (40%) or 20 out of 40 (50%) responses were observed on E in a phase II trial. For these three outcomes, the respective values of the decision criterion probability Pr(u S þ 0.15 < u E j data) are 0.23, 0.47 and 0.85.
Phase II trials with known prognostic subgroup effects
Most designs for phase II trials make the simplifying assumption that a single response probability applies to all patients, that is, patients are homogeneous. Although technically convenient, this assumption may lead to highly flawed conclusions. We will discuss two cases. In the first case, there are known prognostic differences between patient subgroups. We will show that a statistical design that ignores prognosis by assuming one response probability, u E , with E for all patients has a substantial risk of producing false positive or false negative conclusions about the effects of E within subgroups.
For simplicity, we will illustrate the first design in the case of two known prognostic subgroups, good (G) and bad (B). The design may easily be applied more generally in settings with more than two subgroups, although the per-subgroup sample size must be large enough to obtain reasonably reliable results. In this example, to keep track of the four treatment-subgroup combinations, we will denote the subgroup-specific tumor response probabilities by u S;G ¼ Probðresponsejtreated with S in subgroup GÞ;
The method of Wathen et al. [7 ] is based on a Bayesian analysis of covariance (ANCOVA) model for these response probabilities that incorporates the historical subgroup effects seen with S and also allows the subgroups to have different E-versus-S treatment effects. 
Because the four probabilities given above share common parameters and are correlated under this model, it allows one to 'borrow strength' between subgroups. Using the Bayesian formalism, an informative prior on the [subgroup effect] parameters is derived from historical data on S, whereas noninformative priors are assumed for all other parameters as they involve as yet unknown effects of E. Essentially, the data from the trial are used to learn about parameters involving effects of E. The design allows the possibility that E may be more effective than S in one subgroup but equivalent or inferior to S in another. For example, if an improvement of 0.15 in response probability is targeted within each subgroup then the criterion probability Pr(u S,G þ 0.15 < u E,G j data) is used to decide whether to stop or continue in the G subgroup and, similarly,
That is, the method uses subgroup-specific futility stopping rules, with the important provision that each rule is constructed so that the false negative rate (FNR) of each subgroup is controlled below a specified small value such as 0.10. Given a maximum total sample size, M, if accrual to the B subgroup is stopped early but the G subgroup is not stopped, then accrual of G patients is continued until a total of M patients have been enrolled in the trial. In this way, the design spends limited resources in subgroups where E is more likely to provide an advance over S.
As an example, suppose it is known that, with S, the probability of tumor response is 0.45 in patients with good prognosis and 0.25 in patients with bad prognosis. The most common approach that accounts for prognosis is to simply conduct two separate trials, one in G patients and the other in B patients. Using either this approach or the Wathen et al. Computer simulation results comparing these three designs for a 100 patient trial of E monitored in cohorts of size 10 are given in Table 1 . In case 1, the null case where E provides no improvement over S in either subgroup, all three designs have reasonably high early stopping probabilities. The design that ignores subgroups appears to be the best approach of the three because it has the highest probability of correctly rejecting E, 0.86. Equivalently, it has the smallest false positive rate,
The approach of conducting separate trials within subgroups has smaller probabilities of rejecting E than the ANCOVA-based design in each subgroup because it does not borrow strength between subgroups. In case 2, where E achieves the desired 0.15 improvement over S in both subgroups, all three designs control the FNR at 0.10. In case 3, there is treatmentsubgroup interaction as E provides the desired improvement in the B subgroup, from 0.25 to 0.40, but not in the G subgroup. As in case 1, the design that conducts separate trials within subgroups has a lower probability of rejecting E in the G subgroup compared with the ANCOVA-based design. However, the design that ignores subgroups has extremely poor properties, as the probability of stopping early and rejecting E equals 0.41 in both subgroups. This translates into FPR ¼ 1 -0.41 ¼ 0.59 in the G patient subgroup and FNR ¼ 0.41 in the B subgroup. Although these error rates may seem surprisingly large, they illustrate the severe risks that result from ignoring known patient heterogeneity. The flaw in ignoring the prognostic subgroups in this example can be seen by noticing that, accounting for patient heterogeneity, because a response rate of 0.40 is promising for the B subgroup and a response rate of 0.60 is promising for the G subgroup, the single value 0.50 targeted by the simple design is actually too small for G patients and too large for B patients. Unfortunately, Designs accounting for heterogeneity Thall and Wathen 409 the simple but error-prone approach of ignoring prognostic subgroups is most commonly used in phase II trials.
For comparability, all three of these designs considered above had a maximum sample size of 100 and a monitoring schedule that used cohorts of size 10. If one wishes to also consider the commonly used Simon optimal two-stage design [3] , one must assume homogeneity (ignore subgroups) in order to apply this design. In a similar setting where there is a treatment-subgroup interaction, a Simon design with up to 43 patients and nominal FNR and FPR both set equal to 0.10 may have an actual FNR as high as 0.75 (Wathen et al. [7 ] , Table 3 ). This large error rate has two causes, the first being that known prognostic differences are ignored, as in the above example. The second cause arises from the fact that, in general, a two-stage design is far less efficient than a design that monitors the accruing data more frequently.
Phase II trials starting with exchangeable subgroup effects
The second setting is that where, a priori, there is no known prognostic difference between subgroups and it is desired to conduct one trial including all subgroups. To simplify the illustration, we will consider a phase IIA trial where there is no standard treatment with antidisease activity in any subgroup. The usual approach is to target a small fixed positive response probability, P, usually in the range 0.10-0.30. A Gehan design [1] is often used, or a Bayesian rule [17] that stops the trial if Pr(u > P j data) is below a fixed small cut-off. Suppose that one wishes to allow the possibility that the effectiveness of E may differ between subgroups, but one also desires a statistical method in which a response observed in one subgroup leads to a higher estimated response rate in the other subgroups, that is, one wishes to borrow strength between subgroups. Neither assuming one u for all subgroups nor conducting separate trials, one in each subgroup, provides a solution to this problem.
The second design [8] achieves both of the above goals by assuming a Bayesian hierarchical model. As a simple illustration, we will assume that there are four subgroups. Under the hierarchical model, there are four subgroupspecific response probabilities, u 1 , u 2 , u 3 , u 4 , that are generated from a common prior, the parameters of which themselves have second level prior, known as a 'hyperprior,' which induces correlation among the four probabilities. Consequently, for example, data in subgroup 1 affect not only the posterior of u 1 , but also the posteriors of u 2 , u 3 , and u 4 . With this design, each subgroup has its own stopping criterion, Pr(u 1 > P j data) for subgroup 1, Pr(u 2 > P j data) for subgroup 2, etc., where, importantly, the 'data' in each posterior probability includes the data from all 4 subgroups.
To see how this works in practice, suppose that a response probability 0.30 is targeted in each subgroup, we stop accrual to subgroup j if Pr(u j > 0.30 j data) is less than 0.05 and the prior correlation among the response probabilities corresponds to Pr(u 1 > 0.30) ¼ 0.45, whereas Pr(u 2 > 0.30 j 2 responses in 6 patients observed in subgroup 2) ¼ 0.51 and Pr(u 1 > 0.30 j 2 responses in 6 patients observed in subgroup 2) ¼ 0.48. This is the type of information elicited from the oncologists planning the trial that is used to establish the hyperprior ([8], section 4]. larger. This illustrates how the prior correlation induced by the hierarchical model affects the posteriors, and also the fact that, as with any reasonable Bayesian model, the accumulating data eventually overcome any prior assumptions.
Conclusion
We have briefly reviewed two general Bayesian methods that account for heterogeneity in phase II. More complex, application-specific Bayesian methods that account for patient covariates using regression models have been described [18, 19, 20 ] . A general conclusion is that treatment-subgroup interactions may cause simple phase II methods to have extremely large false positive and false negative error rates within subgroups. Consequently, not only accounting for patient subgroups, but also accounting for the possibility of treatment-subgroup interactions appear to be very important. Alternatively, if an investigator feels strongly that subgroup effects and treatmentsubgroup interactions are highly unlikely, then a conventional design may be used.
A frequentist, hypothesis test-based approach to phase II trials that accounts for heterogeneity has also been proposed [21] , but this method does not allow the possibility of treatment-subgroup interactions and thus suffers from potentially very large error rates within subgroups.
We have not addressed the related but very different problem of identifying new prognostic subgroups, which usually is not feasible in phase II due to limited sample sizes [22] . 
